US enteropathy warning for olmesartan
This article was originally published in Scrip
Executive Summary
The US FDA has approved changes to labels for products containing olmesartan medoxomil to warn that the antihypertensive can cause a potentially serious intestinal problem known as sprue-like enteropathy (SLE).